Repros(R) Therapeutics Reports Outcome of Type B Meeting with FDA Regarding Androxal(R) in the Treatment of Secondary Hypogonadism FDA agrees in general with Androxal development program and ...

Repros Therapeutics (NASDAQ: RPRX) stock has rallied an impressive 60% in the last month on renewed confidence in the company’s pipeline, which consists of the male fertility drug Androxal which ...

Repros Therapeutics reported it has received Institutional Review Board (IRB) approval to commence a Phase 2b study of Androxal (enclomiphene) in men with secondary hypogonadism. The study will enroll ...

Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of ...

Repros Therapeutics Inc.'s CEO Joseph Podolski acknowledged the "nauseating" Wall Street ride for the company of late, but told investors during a conference call that "with time and continued ...

Repros Therapeutics Inc. shares rallied in the extended session Wednesday after the drug developer said the Food and Drug Administration will review its drug to treat overweight men with low ...

Repros Therapeutics Inc. (NASDAQ:RPRX) caught the attention of biotech investors after its ~120% rally in May, which sent the stock from a market cap of approximately $63 million to its current $140 ...

Repros Therapeutics Inc. RPRX announced that the new drug application for its lead pipeline candidate, enclomiphene (previously known as Androxal), is scheduled to be reviewed by the FDA’s Division of ...

This article was reviewed by Felix Gussone, MD. Testosterone plays a major role in many aspects of men’s health, including drive, reproductive function, muscle mass, and mood. So if your levels dip ...

The estrogen antagonist oral enclomiphene citrate (formerly known as Androxal, Repros Therapeutics), raises serum total testosterone levels while maintaining sperm counts in the normal range in men ...